May 2006

Topical Calcineurin Inhibitors for Atopic DermatitisBalancing Clinical Benefit and Possible Risks

Author Affiliations

Copyright 2006 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2006

Arch Dermatol. 2006;142(5):633-637. doi:10.1001/archderm.142.5.633

This editorial has been written at the request of the National Eczema Association for Science and Education (NEASE), San Rafael, Calif. The purpose is to provide an objective, independent view of the evidence surrounding the effectiveness and possible adverse effects of topical calcineurin inhibitors (TCIs) in response to the recent US Food and Drug Administration (FDA) concerns.1 This editorial is meant for patients with atopic dermatitis (AD) and their health care providers.

First Page Preview View Large
First page PDF preview
First page PDF preview